Who can use Truqap(Capivasertib)?
The specific medical condition the drug is approved to treat.
Indication
TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Its use is contingent upon the presence of one or more alterations in the PIK3CA, AKT1, or PTEN genes, as detected by an FDA-approved test, following disease progression on or after endocrine therapy.
